Literature DB >> 9138629

Leydig cell hyperplasia and adenoma formation: mechanisms and relevance to humans.

E D Clegg1, J C Cook, R E Chapin, P M Foster, G P Daston.   

Abstract

Leydig cell adenomas are observed frequently in studies evaluating the chronic toxicity of chemical agents in laboratory animals. Doubts have been raised about the relevance of such responses for human risk assessment, but the question of relevance has not been evaluated and presented in a comprehensive manner by a broad group of experts. This article reports the consensus conclusions from a workshop on rodent Leydig cell adenomas and human relevance. Five aspects of Leydig cell biology and toxicology were discussed: 1) control of Leydig cell proliferation; 2) mechanisms of toxicant-induced Leydig cell hyperplasia and tumorigenesis; 3) pathology of Leydig cell adenomas; 4) epidemiology of Leydig cell adenomas; and 5) risk assessment for Leydig cell tumorigens. Important research needs also were identified. Uncertainty exists about the true incidence of Leydig cell adenomas in men, although apparent incidence is rare and restricted primarily to white males. Also, surveillance databases for specific therapeutic agents as well as nicotine and lactose that have induced Leydig cell hyperplasia or adenoma in test species have detected no increased incidence in humans. Because uncertainties exist about the true incidence in humans, induction of Leydig cell adenomas in test species may be of concern under some conditions. Occurrence of Leydig cell hyperplasia alone in test species after lifetime exposure to a chemical does not constitute a cause for concern in a risk assessment for carcinogenic potential, but early occurrence may indicate a need for additional testing. Occurrence of Leydig cell adenomas in test species is of potential concern as both a carcinogenic and reproductive effect if the mode of induction and potential exposures cannot be ruled out as relevant for humans. The workgroup focused on seven hormonal modes of induction of which two, GnRH agonism and dopamine agonism, were considered not relevant to humans. Androgen receptor antagonism, 5 alpha-reductase inhibition, testosterone biosynthesis inhibition, aromatase inhibition, and estrogen agonism were considered to be relevant or potentially relevant, but quantitative differences may exist across species, with rodents being more sensitive. A margin of exposure (MOE; the ratio of the lowest exposure associated with toxicity to the human exposure level) approach should be used for compounds causing Leydig cell adenoma by a hormonal mode that is relevant to humans. For agents that are positive for mutagenicity, the decision regarding a MOE or linear extrapolation approach should be made on a case-by-case basis. In the absence of information about mode of induction, it is necessary to utilize default assumptions, including linear behavior below the observable range. All of the evidence should be weighed in the decision-making process.

Entities:  

Mesh:

Year:  1997        PMID: 9138629     DOI: 10.1016/s0890-6238(96)00203-1

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  16 in total

1.  Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters.

Authors:  Edward Anthony Emmett; Hong Zhang; Frances Susan Shofer; David Freeman; Nancy Virginia Rodway; Chintan Desai; Leslie Michael Shaw
Journal:  J Occup Environ Med       Date:  2006-08       Impact factor: 2.162

2.  Seasonal reproduction of male Gambusia holbrooki (eastern mosquitofish) from two Florida lakes.

Authors:  Thea M Edwards; Hilary D Miller; Gunnar Toft; Louis J Guillette
Journal:  Fish Physiol Biochem       Date:  2013-02-13       Impact factor: 2.794

3.  Histologic and histomorphometric changes of testis following oral exposure to methyl tertiary-butyl ether in adult rat.

Authors:  S Gholami; M Ansari-Lari; L Khalili
Journal:  Iran J Vet Res       Date:  2015       Impact factor: 1.376

4.  Community exposure to perfluorooctanoate: relationships between serum concentrations and exposure sources.

Authors:  Edward Anthony Emmett; Frances Susan Shofer; Hong Zhang; David Freeman; Chintan Desai; Leslie Michael Shaw
Journal:  J Occup Environ Med       Date:  2006-08       Impact factor: 2.162

5.  Effect of testicular morphology on embryo development to the blastocyst stage after round spermatid injection.

Authors:  Gokhun Ozmerdiven; Yavuz Guler; Eren Sahin; Zeynep Tatar; Akif Erbin; Ebubekir Dirican; Ahmet Hakan Haliloglu
Journal:  Am J Clin Exp Urol       Date:  2021-12-15

Review 6.  Environmental endocrine disruption: an effects assessment and analysis.

Authors:  T M Crisp; E D Clegg; R L Cooper; W P Wood; D G Anderson; K P Baetcke; J L Hoffmann; M S Morrow; D J Rodier; J E Schaeffer; L W Touart; M G Zeeman; Y M Patel
Journal:  Environ Health Perspect       Date:  1998-02       Impact factor: 9.031

7.  Precocious puberty and Leydig cell hyperplasia in male mice with a gain of function mutation in the LH receptor gene.

Authors:  Stacey R McGee; Prema Narayan
Journal:  Endocrinology       Date:  2013-07-16       Impact factor: 4.736

8.  Multiple structural and functional abnormalities in the p450 aromatase expressing transgenic male mice are ameliorated by a p450 aromatase inhibitor.

Authors:  Xiangdong Li; Leena Strauss; Sari Mäkelä; Tomi Streng; Ilpo Huhtaniemi; Risto Santti; Matti Poutanen
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

9.  Expression of the TGF-beta1 system in human testicular pathologies.

Authors:  Candela R Gonzalez; María E Matzkin; Mónica B Frungieri; Claudio Terradas; Roberto Ponzio; Elisa Puigdomenech; Oscar Levalle; Ricardo S Calandra; Silvia I Gonzalez-Calvar
Journal:  Reprod Biol Endocrinol       Date:  2010-12-02       Impact factor: 5.211

10.  Successful drug development despite adverse preclinical findings part 2: examples.

Authors:  Robert A Ettlin; Junji Kuroda; Stephanie Plassmann; Makoto Hayashi; David E Prentice
Journal:  J Toxicol Pathol       Date:  2010-12-16       Impact factor: 1.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.